Charles Chuah

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

Hagop M. Kantarjian, Neil P. Shah, Andreas Hochhaus et al. · New England Journal of Medicine · 2010 · 1.6K citations

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

Jörge E. Cortes, D. W. Kim, Javier Pinilla‐Ibarz et al. · New England Journal of Medicine · 2013 · 1.1K citations · Full text

Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial

Jörge E. Cortes, Giuseppe Saglio, Hagop M. Kantarjian et al. · Journal of Clinical Oncology · 2016 · 916 citations · Full text

Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Jörge E. Cortes, Dong‐Wook Kim, Javier Pinilla‐Ibarz et al. · Blood · 2018 · 572 citations · Full text

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

King Pan Ng, Axel M. Hillmer, Charles Chuah et al. · Nature Medicine · 2012 · 550 citations

Intrinsic Resistance, Tumor Biology, Radiation Oncology +11